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Abstract
In this report, we describe the development of a modified adeno-
associated virus (AAV) capsid and promoter for transduction of
retinal ON-bipolar cells. The bipolar cells, which are post-synaptic
to the photoreceptors, are important retinal targets for both basic
and preclinical research. In particular, a therapeutic strategy under
investigation for advanced forms of blindness involves using
optogenetic molecules to render ON-bipolar cells light-sensitive.
Currently, delivery of adequate levels of gene expression is a limit-
ing step for this approach. The synthetic AAV capsid and promoter
described here achieves high level of optogenetic transgene expres-
sion in ON-bipolar cells. This evokes high-frequency (~100 Hz)
spiking responses in ganglion cells of previously blind, rd1, mice.
Our vector is a promising vehicle for further development toward
potential clinical use.
Keywords adeno-associated virus; capsid library; multi-electrode array;
optogenetics; promoter optimization
Subject Categories Genetics, Gene Therapy & Genetic Disease; Neuroscience
DOI 10.15252/emmm.201404077 |Received 17 March 2014 |Revised 4 July
2014 | Accepted 7 July 2014 | Published online 4 August 2014
EMBO Mol Med (2014) 6: 1175–1190
Introduction
Much of the early-stage processing of visual inputs occurs within the
retinal bipolar cells, and the failure of available vectors to effectively
transduce these cells has impacted both basic research and blindness
therapies. In this article, we describe a synthetic adeno-associated
virus (AAV) capsid and promoter for transduction of ON-center
bipolar cells.
The bipolar cells carry the light-induced vertical flow of informa-
tion from photoreceptors in the outer part of the retina to ganglion
cells in the inner part of the retina. Thereby, they serve not only as
a conduit from outer to inner retina: The bipolar cells are also “inte-
grating centers” for the retina’s response to light (Masland, 2012).
To facilitate downstream processing by ganglion cells, the bipolar
cells need to combine information from two sources: information
coming from photoreceptors on the light hitting the center of the
receptor field, and indirect information pertaining to the surround,
as shaped by inhibitory inputs from neighboring cells. A second
level of processing is achieved by having the two classes of bipolar
cells, ON-center (ON-bipolars) and OFF-center (OFF-bipolars),
provide parallel information channels responding to increases
versus decreases in light intensity. Extensive molecular and physio-
logical studies have revealed how bipolar cells transform informa-
tion arriving from photoreceptors, and transmit it to retinal ganglion
cells (Masland, 2012). In vitro systems, transgenic models, and
mutation analysis have been used to great effect to characterize the
bipolar cells’ differing glutamate receptors, signaling proteins, and
ion channels (Hanna & Calkins, 2007; Dhingra et al, 2008; Audo
et al, 2009; Peachey et al, 2012; Ray et al, 2014). However, the
molecular effort has been hampered by the lack of a suitable vector
to further probe bipolar cell function through conditional labeling
and gene knockdown studies.
The need for such a vector is especially pressing in translational
research. Recent efforts have pursued a therapeutic strategy using
optogenetic molecules to render inner retinal cells light-sensitive (Bi
et al, 2006; Lagali et al, 2008). These efforts have revealed how
light-activated channels, such as the various channelrhodopsins
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that have lost photoreceptors due to degeneration. Expressed in reti-
nal neurons, the channel will, upon illumination of the cell, bypass
the phototransduction cascade and enable direct membrane depolar-
ization. Channelrhodopsin-2 (ChR2) expression in the ON-bipolar
cells of retinas from blind rd1 mice has been shown to make these
cells capable of detecting, and also processing, the input visual
signal before relaying the information to the ganglion cells and
restoring some sensitivity to increasing light (Lagali et al, 2008;
Doroudchi et al, 2011). However, efficient targeting of ON-bipolar
cells with AAVs expressing sufficient levels of ChR2 to allow gang-
lion cells to fire at high action potential frequencies (~100 Hz) has
not been achieved. This likely requires not only optimized optoge-
netic tools (Williams & Deisseroth, 2013), but also optimized AAV
capsids for ON-bipolar cell targeting and specific promoters
elements to improve optogenetic expression.
Vectors based on the small (25 nm) AAV offer the best chance
for effective gene delivery. Recent clinical trials using this vector
platform have proven to be safe and efficacious in retinal gene ther-
apy (Bainbridge et al, 2008; Hauswirth et al, 2008; Maguire et al,
2008; Simonelli et al, 2010). Follow-up studies have also shown
AAV to be effective in its delivery role and in maintaining an excel-
lent safety record for an extended duration of treatment (Maguire
et al, 2008; Cideciyan et al, 2009). To circumvent some of its limita-
tions, such as tissue penetration, efforts have been made to reengi-
neer the virus (Muzyczka & Warrington, 2005; Mitchell et al, 2010;
Bartel et al, 2011; Yang et al, 2011; Kienle et al, 2012), notably
generating an AAV variant capable of reaching the outer nuclear
layer from the vitreous (Dalkara et al, 2013). In addition, the retar-
geting properties of AAV mutants derived through random peptide
insertion at the heparan sulfate proteoglycan (HSPG) receptor bind-
ing site of the AAV capsid have been investigated (Girod et al, 1999;
Perabo et al, 2006). More recently retargeting has been achieved by
altering the region of the AAV8 and AAV9 capsid that corresponds
to the HSPG-binding site of AAV2 (Michelfelder et al, 2011).
In this work, we have adapted the capsid library approach to
enhance AAV-mediated retinal bipolar cell expression. A favorable
variant, derived through directed selection from a library of serotype
AAV8 capsid mutants, was identified. In parallel, we restricted gene
expression to the ON-bipolar cells by further amplifying expression
from a validated enhancer sequence of the ON-bipolar-cell-specific
gene Grm6. We estimate that this synthetic AAV/promoter combina-
tion can drive GFP expression in 59% of the ON-bipolar cells in
mice. This vector will enable further investigation of the role that
bipolar cells play in retinal processing and has the potential to
recruit the bipolar cells for retinal gene therapy.
Results
Rationale for targeted mutagenesis of AAV8 capsid
Of the many cell types in the retina, the bipolar cells have thus far
been the least amenable to transduction by AAV. This may be due
to a lack of appropriate receptor expression on the cell surface to
mediate uptake, or the presence of an extracellular inhibitory factor
on or near the cell surface, or intrinsic factors governing viral traf-
ficking and processing in the cell, or a lack of an appropriate
promoter. We argued that the lack of AAV-mediated expression in
the bipolar cells is partly due to failure of the capsid to bind and
transduce this cell type. When injected subretinally, AAV2/8 was
shown to penetrate deeper into the retinal layers than other sero-
types (Vandenberghe et al, 2011). Due to this capacity to “reach”
the bipolar cell layer, the AAV8 capsid was chosen as the template
for modification.
A 9-amino acid stretch of a conformationally variable region of
the AAV8 capsid protein between positions 585 and 593 was
specifically selected for its potential to alter receptor attachment
and cellular transduction properties of the virus. This was based
on information from 3-D models and targeted mutagenesis studies
of the capsid (Xie et al, 2002; Padron et al, 2005; Nam et al, 2007;
Gurda et al, 2012). The AAV shell is assembled from 60 copies of
viral proteins (VP), VP1 (87 kDa), VP2 (73 kDa), and VP3
(61 kDa). The conserved core of each VP subunit consists of an
eight-stranded b-barrel motif and an a-helix (Xie et al, 2002). The
outer surface of the capsid is formed of large loops that connect
the strands of the b-barrel. For example, the residues from amino
acids 585–594 of the AAV8 capsid protein encompass finger-like
loops for one VP subunit. The amino acid sequences and structural
topology of these large outer loops have been reported to facilitate
tissue tropism and transduction efficiency (Agbandje-McKenna &
Kleinschmidt, 2011). The loop formed by the residues from 585 to
594 contributes to the top of the protrusions that surround the
icosahedral threefold axes that are formed through symmetric
interactions between the VPs. Thus, this 9-amino acid region holds
a prominent position on the capsid and includes sites shown in
some serotypes (notably AAV2) to be critical for heparan sulfate
binding and cellular uptake (Kern et al, 2003; Opie et al, 2003).
The nine residues, which are conserved in many serotypes, are
altered in the AAV8 capsid, suggesting that AAV8 does not show
any affinity for heparan sulfate (Wobus et al, 2000; Wu et al,
2006). Furthermore, an analogous domain within the heparan
sulfate binding region was previously interchanged between AAV
serotypes and shown to alter tropism profiles dramatically (Asokan
et al, 2010). It is possible that this surface-exposed epitope region
of residues 585–594 in AAV8 is amenable to changes that may
influence tissue tropism and transduction characteristics and still
yield viable capsids.
Strategy used to modify AAV tropism
From crystallography studies carried out at 2.6-A ˚ resolution, Nam
et al have attributed the lack of heparan sulfate binding by AAV8 to
be in part due to the structural differences in the region utilized for
receptor recognition by AAV2 [highlighted in red in Fig 1A, from
PDB 2QA0, (Nam et al, 2007)]. Two critical residues, R585 and
R588, are particularly necessary in order for AAV2 to bind heparan
sulfate (Kern et al, 2003; Opie et al, 2003). These positions align
with Q588 and T591, respectively, in AAV8 (Lochrie et al, 2006). To
produce an AAV capsid library, the residues from amino acids 585
to 593 of the AAV8 capsid were replaced with a mixture of
sequences to produce randomized codons (Fig 1B). To maximize
diversity while reducing the chances of introducing a premature
stop, the NNK saturation mutagenesis strategy was applied which
should eliminate all stops with the exception of TAG (Muranaka
et al, 2006).
EMBO Molecular Medicine Vol 6 |N o9 | 2014 ª 2014 The Authors
EMBO Molecular Medicine Bipolar cell transduction to restore vision Therese Cronin et al
1176This mutated capsid region was cloned into the pAAV8Caps-Lib
vector designed for AAV library production and encoding a red fluo-
rescent protein (Supplementary Fig S1B). This plasmid, which has
the AAV2 ITRs flanking the minimal rep/cap gene of AAV8 posi-
tioned in reverse orientation to the cDNA for dsRed, was used to
produce the AAV viral library. An estimated plasmid library degen-
eracy of 2.6 × 10
5 cfu/ml was derived from colony-counting of
plated test ligation following initial transformation.
The plasmid was cotransfected with a helper plasmid into
HEK293 cells for library production and preparation. An infectious
titer of 1 × 10
5 IU/ll was estimated for the resulting viral library by
limiting dilution analysis on HEK293 cells. Up to 2 ll of the viral
library was subretinally injected into Grm6-GFP transgenic mice, in
which the ON-bipolar cells are labeled with EGFP expressed under
the control of the Grm6 promoter. After 3 weeks, cell dissociation
and cell sorting (FACS) were used to isolate the ON-bipolar cells.
For most of the tested serotypes, AAV-mediated retinal expression
has been shown to require 2–3 weeks to reach optimal levels
(Stieger et al, 2011). These cells included a subset of cells double-
labeled with EGFP and dsRED, that is, library-transfected ON-bipo-
lar cells. The sorted EGFP-labeled cells were lysed, and the mutant
region of the capsid was amplified by PCR and recloned back into
the pAAV8Caps-Lib plasmid for a second round of viral library
production (library R1) and injection. The library R1 thus carried a
population of virus particles that, through passive selection, were
capable of ON-bipolar cell transduction.
However, it was desirable to select for viruses that could effec-
tively compete with the wild-type virus. Therefore, in the second
round, the viral library was spiked with the unmutated virus
AAV2/8-dsRed, which in effect served as a competing selective
force (Fig 1C). From this round, unmutated and mutant sequences
were found in double-positive EGFP/dsRED-labeled cells (trans-
duced ON-bipolar cells) with only unmutated AAV8 capsid
sequences isolated from the dsRed-positive, EGFP-negative cells
(transduced non-bipolar cells) (Fig 1D). The R1 library carries a
heterogeneous mix of capsids; each one producing a unique virus
at greatly reduced titer compared to the wild-type co-injected
AAV2/8-dsRed. Therefore, it is expected that mutant viruses
cannot compete with the wild-type virus in the non-bipolar cells
of the retina. However, as the wild-type virus is inefficient at
transducing bipolar cells, the R1 library-derived viruses can
compete for bipolar cell transduction, and the mutant sequences
emerge. From the double-positive red/green cells, the AAVs were
isolated and sequenced. Six variants were identified in DNA
samples from 44 colonies (Table 1). It is notable that the wild-
type capsid sequence was considerably more abundant (30 wild-
type sequences versus 14 mutant sequences, Table 1). This was
expected, due to the very dilute titer for each individual variant.
The WT viral titer is 1 × 10
12 gc/ml, hence the emergence of any
mutant sequence against a saturating WT background is signifi-
cant.
One variant (variant 5) carried a stop codon and was likely to
have been carried through the screen when packaged in another
viable capsid. During viral production in the packaging HEK293 cell,
the stop-codon-containing sequence may have been taken up by a
capsid encoded by another AAV genome within the cell. By using a
low plasmid/(packaging-cell) ratio, we hope to minimize the
number of alternative AAV genomes within the cell. Nonetheless,
due to the random nature of the transfection, it is not guaranteed
that the genome encoding a capsid will be the same as the genome
packaged within the encoded capsid and this most likely accounts
for the presence of AAV8/BP5. We have confirmed that this sero-
type is non-viable in luminescence assay (Fig 1E). Its persistence in
the screen may be accounted for when you consider that the TAG
residue may arise 1.56% of the time (1/64) such that across 9 resi-
dues its frequency will be 14%. It served as a negative control for
titration.
The variant sequences were processed for further analysis, and
four variants were further selected based on the titration data from
small-scale (Fig 1E and Supplementary Fig S3) and large-scale
preps (Fig 1F) as well as structural predictions of the targeted
region anticipated to potentially affect receptor/ligand interactions
(Supplementary Fig S2).
Analysis of AAV2/8BP2 in the retina using a
non-cell-specific promoter
AAV vectors were created using each of the selected mutant
sequences in place of the wild-type AAV8 capsid gene, and this
modified rep/cap plasmid was used to produce AAV(EF1a-EGFP)
viruses. Variant 6 yielded low titer and therefore was not used in
any further analysis. For this initial analysis, the normal recombi-
nant AAV2/8 virus was injected at a titer of 1 × 10
13 gc/ml and the
variant viruses injected at a titer of 1 × 10
12 gc/ml. Mouse retinal
sections were examined 3 weeks after subretinal or intravitreal
injection with the selected AAV variants (Fig 2A and B, Supplemen-
tary Fig S4). These qualitative tests using a generic promoter led to
the selection of AAV2/8BP2 for further investigation. The cell-type
transduction pattern was assessed based on cell soma position in
the retina, with the strata of the IPL delineated using a marker for
choline acetyl transferase (anti-ChAT). The normal recombinant
AAV2/8 shows fluorescence in a diverse range of cell types, with
the sparsest fluorescence between the outer (OPL) and inner (IPL)
plexiform layers, where the bipolar cell subtypes are found (upper
panel of Fig 2A and B). For variant 2, the strongest fluorescent
staining was found between the OPL and IPL (lower panel Fig 2A
and B), with bipolar and amacrine cells stained. In addition, the
photoreceptor cell bodies in the outer nuclear layer (ONL) and their
outer segments, as well as cells in the ganglion cell layer (GCL), are
stained.
Based on these data, a purified large-scale preparation of AAV2/
8BP2 was prepared and in vitro and in vivo transduction was
assayed. This virus was confirmed to transduce HEK293 cells in
vitro in a similar way to the parental AAV2/8, suggesting that the
modified epitope was not having a significant negative impact on
the natural tropism (Fig 2C). Adult C57Bl6 mice were subretinally
injected with genomic-titer-matched AAVs expressing EGFP under
the control of the EF1a promoter and made using either the unmu-
tated AAV8 capsid or the mutant AAV8BP2. After 3 weeks, the reti-
nas were dissociated and processed for FACS analysis. Cell counts
(Fig 2D) show 20% transduction of retinas injected with AAV2/8
versus 32% transduction of retinas injected with AAV2/8BP2.
However, this difference in transduction of total retinal cells is non-
significant. In order to determine what proportion of the transduced
cells are ON-bipolar cells, a pool of 80,000 cells was taken from each
sorted fraction, and the relative expression of retinal genes in the
ª 2014 The Authors EMBO Molecular Medicine Vol 6 |N o9 | 2014
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1178green and non-green cell populations was tested using RT-qPCR.
The expression of bipolar cell-specific genes, Grm6 and the long
form of a transient receptor potential cation channel, TrpM1L (Zeitz
et al, 2005; Morgans et al, 2009), were examined to determine the
number of ON-bipolar cells in the transduced cell populations. A
120% increase in Grm6 expression, and a 67% increase in TrpM1L
expression, was detected for AAV2/8BP2BP2 compared to AAV2/8-
injected retinas, with the gene expression normalized to b-actin
levels (Fig 2E). In contrast, equivalent expression levels of cone
opsin genes were measured between the pools for AAV2/8 versus
AAV2/8BP2 retinas (Fig 2F). The gene expression from the cells
suggests that improved targeting to the bipolar cells is being
achieved with the variant AAV, even when coupled with a strong
constitutive promoter such as EF1a. This validated further develop-
ment of the AAV2/8BP2 virus for bipolar cell-enriched transduction.
Development of a strong and specific ON-bipolar cell promoter
A specific metabotropic glutamate receptor (mGluR6) is responsible
for synaptic transmission from photoreceptors to ON-type bipolar
cells (Shiells & Falk, 1994; Masu et al, 1995; Ueda et al, 1997). This
receptor is expressed exclusively in the bipolar cell layer, where it is
confined to the postsynaptic site of ON-bipolar cells (Nomura et al,
1994; Vardi & Morigiwa, 1997) and is encoded by the Grm6 gene.
The approximate range of the Grm6 promoter relative to the GRM6
transcriptional start site has been known for some time. Ueda et al
(1997) generated transgenic mice using the 50 flanking mouse Grm6
sequence fused to a reporter gene. This 10-kb region was capable of
directing the cell-type-specific and developmentally regulated
expression of the Grm6 gene. Kim et al refined the sequence to a
200-bp critical enhancer region ( 8126 to  7927 relative to the first
Table 1. Altered sequence of the AAV8 capsid in amino acid region 585–594 in variants selected from library screen.
The number of colonies in which the variant was found (out of 44) is listed in the first column.
WT
30 colonies
CAG CAG CAA AAC ACG GCT CCT CAA ATT
Gln Gln Gln Asn Thr Ala Pro Gln Ile
PPPP(P)( N) P
a P (N)
b
Var 1
2 colonies
TAT CTT ATG CGT TAT ATT GGT GTT TTT
Tyr Leu Met Arg Tyr Ile Gly Gly Phe
PN
b N
b B
b P (N)
b NNN
b
Var 2
4 colonies
CCT GAG GGG ACG GCG ATG AGT CTT CCG
Pro Glu Arg Thr Ala Met Ser Leu Pro
P
a AB
a NNN
b PN
b P
a
Var 3
3 colonies
AGT TTT AGT CGT GCG GTT CTT TGT GAT
Ser Phe Ser Arg Ala Val Leu Cys Asp
PN
b PB
a NN
b N
b PA
Var 4
2 colonies
CAT TGT GTG GAT TGT TGT GCG TCT TAT
His Cys Val Asp Cys Cys Ala Ser Tyr
PN
b PP(N) PP
Var 5
1 colony
CAT ACT GAG TAT ATG AGT GAG TAG CTC
Jis Thr Glu Tyr Met Ser Glu –
c Leu
B
a NAPN
b P A Stop N
b
Var 6
2 colonies
CCG ATT TTT GTT GGG TGT TCT GTG CTT
Pro Ile Phe Val Gly Cys Ser Val Leu
P
a (N)
b N
b N
b NPPN
b N
b
B, basic; A, acidic; P, polar; N, non-polar.
aHydrophyllic.
bHydrophobic.
cStop signal.
Figure 1. AAV8 viral library preparation.
A The secondary structure of the AAV capsid 8 (PDB:2QA0) with the region targeted for mutation highlighted in red.
B Electropherogram of AAV8 capsid sequence from nucleotide 1731 to 1800 containing the mutated region between amino acids 585 and 593.
C The schema for AAV capsid variant isolation: In round 1, the AAV library, “AAV2/8lib-dsRed” was subretinally injected into GRM6-GFP mice. After 4 weeks, the retinas
were dissociated and green cells isolated by FACS. In round 2, the viral library filtered through round 1 was used to create a titrated AAV2/8lib-dsRed library R1. This
was mixed with a non-mutated AAV2/8-dsRed, serving as competing virus, and the viral mix cosubretinally injected into GRM6-GFP mice. From round 2, green/red
and red-only cells were isolated by FACS for further analysis of sequence variants.
D The electropherograms of AAV capsid sequences amplified by PCR from the cells with only non-mutated sequences isolated from red-only cells (a) and non-
mutated as well as variant sequences present in the red/green population (b).
E, F The titers of the novel viruses were determined by luciferase assay for small-scale preparations (E) and RT-qPCR for large-scale preparations (F).
◂
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1180nucleotide of GenBank accession number BC021919, NIH) that
could be used to drive reporter gene expression specifically in ON-
bipolar cells (Kim et al, 2008; Lagali et al, 2008). We tested expres-
sion constructs in which the minimal SV40 promoter was preceded
by multiple 200-bp enhancer elements. The constructs tested carried
2, 4, 8, or 16 copies of the 200-bp enhancer cassettes in tandem.
The strength of reporter gene expression increased with multiple
enhancer cassettes, plateauing with the use of four enhancer
elements (4 × Grm6). This arrangement facilitated a high level of
expression restricted to the ON-bipolar cells in electroporated mouse
retinal explants (Supplementary Fig S5). However, it did not achieve
this level of expression when packaged in wild-type AAV vectors
and subretinally injected into mice. To test how the variant AAV
works in concert with the 4 × Grm6 promoter, we injected C57Bl/6
mice with AAV2/8 or AAV2/8BP2 viruses carrying 4 × Grm6-ChR2-
EGFP constructs. Both subretinal and intravitreal injection routes
were examined (Fig 2G and H). Both injection routes yield stronger
fluorescence using the AAV2/8BP2 virus compared to the AAV2/8
virus. This was evident for stained as well as unfixed and unstained
retinas (right-hand panel of Fig 2G and H). Subretinal injection of
AAV2/8BP2 gave stronger fluorescence than intravitreal injection,
though the latter gave a wider spread of transduction. There was
non-specific staining of the ONL and outer segments with the
AAV2/8BP2 vector following subretinal injection. At lower titers
(7 × 10
12 gc/ml), these off-target effects were not observed (Supple-
mentary Fig S6). To facilitate comparison with the wild-type vector,
it was necessary to use high titers as no signal was obtained from
AAV2/8-4 × GRM6-injected retinas at titers below 1 × 10
12 gc/ml.
Quantification of AAV2/8BP2 transduction in the retina using a
bipolar-cell-specific promoter
Images of the retinas at low magnification (10×) show the difference
in fluorescence intensity in the INL of retinas injected with the wild-
type virus AAV2/8 (4 × GRM6-EGFP) virus compared to the variant
AAV2/8BP2 (4 × GRM6-EGFP) virus (Fig 3A). The laser power of
the confocal microscope was unchanged in comparisons between
retinas, and as a result a saturating fluorescence signal was
unavoidable in the AAV2/8BP2-4 × GRM6 retinas. To quantify the
improvement in transduction observed, wholemounts of fresh,
unfixed retinas from injected mice were used. Local z-projections
encompassing the ON-bipolar cell body were imaged, and the
compressed stack used for fluorescent spot detection (Fig 3B).
These cell counts across three randomly chosen regions of each of
five retinas show that an average of 2.3 fluorescent cells were found
in a 60 lm
2 area in the AAV2/8 group compared to 89 fluorescent
cells for the AAV2/8BP2-injected group (Fig 3C).
In order to test the efficiency of the combined AAV2/8BP2 capsid
and 4 × GRM6 promoter in optogenetic stimulations, we created
AAVs with AAV2/8BP2-4 × GRM6 or AAV2/8-4 × GRM6 capsid–
promoter combination, which expressed the channelrhodopsin-2
variant “CatCh”. This channelrhodopsin shows reduced desensitiza-
tion due to a L132C mutation, and as a consequence yields
increased photocurrent at a given light intensity (Kleinlogel et al,
2011). Before embarking on studies to test light stimulation in the
retina, the specificity and efficiency of transduction by these vectors
had to be tested. Therefore, immunolabeling for the ON-bipolar-cell-
specific protein TrpM1L was carried out on retinas from mice
injected with virus expressing 4 × GRM6-CatCh-EGFP (Fig 3F).
Counting cells in slices from confocal images of the retinas deter-
mined the level of colocalization between the virally expressed GFP
and the TrpM1L-immunolabel in cells. The number of colabeled
cells was normalized either to the total trpM1L-labeled cells to deter-
mine the efficiency of transduction, or to the total number of GFP-
labeled cells to determine the specificity of transduction. Compared
to wild-type virus, the AAV2/8BP2 retinas showed a threefold
increase in ON-bipolar-cell transduction efficiency (Fig 3D). The
wild-type and the AAV2/8BP2 retinas showed similar specificity in
transduction of bipolar cells, with 80–83% of the green virus-
transduced cells also labeling as ON-bipolar cells (Fig 3E).
A FACS analysis was also carried out to more precisely determine
the difference in transduced cell number between the variant and
wild-type viruses 3 weeks post-injection. We aimed to quantify the
range of fluorescence intensity for both viruses and therefore took
counts from each of seven subdivisions of the GFP scatter-plot
(Fig 3G). Both subretinal (upper panel of Fig 3H) and intravitreal
(lower panel of Fig 3H) injection routes were examined. The cells
that were brightest, encompassing the subdivisions from Fr12 to
Fr14, have a combined percentage of 0.5% of the total retinal cells
for mice injected with AAV2/8 versus 4.96% transduction for mice
injected with AAV2/8BP2. The RNA from the Fr12-14 pool of cells
from AAV2/8BP2 mice was isolated for expression analysis.
However, as there were too few corresponding cells in the Fr12-14
cells from AAV2/8 mice this was not included in the analysis.
Instead, a comparative study was carried out between this RNA and
the RNA from total unsorted retinal cells. We compared the expres-
sion of three genes that were shown by Siegert et al (2009) to be
differentially expressed among the ON-bipolar cell subtypes. Kcng4
Figure 2. Analysis of transduction properties of AAV2/8BP2 virus.
A, B Representative 20× confocal images of immunostained vibratome sections from retinas of mice subretinally injected (A) or intravitreally injected (B) with viruses.
The upper panels show AAV2/8(EF1a-EGFP) injected retinas, and the lower panels show AAV2/8BP2(EF1a-EGFP) injected retinas. The retinas are stained for EGFP
(green), cell nuclei (gray), and for the inner plexiform layer strata using choline acetyltransferase (ChAT) (magenta). POS, photoreceptor outer segments; ONL, outer
nuclear layer; OPL, outer plexiform layer; IPL, inner plexiform layer; GCL, ganglion cell layer.
C The number of genome copies per cell was estimated for purified AAV2/8BP2 compared to AAV2/8 following transduction of HEK293 cells.
D Cell counts from FACS analysis of retinas from mice (n = 4) subretinally injected with AAV2/8(EF1a-EGFP) or AAV2/8BP2(EF1a-EGFP).
E RT-qPCR on RNA from the sorted cells used to determine bipolar cell gene expression levels with 120% increase in Grm6 expression (P = 0.05) and 67% increase in
TrpM1L expression (P = 0.04) in the AAV2/8BP2(EF1a-EGFP) cell pool.
F Equivalent expression levels measured between cell pools for the cone photoreceptor genes Opnmwl and Opnswl.
G Representative 40× confocal images of sections from the retinas of mice subretinally injected with AAV2/8(4 × GRM6-EGFP) (upper panel) and AAV2/8BP2
(4 × GRM6-EGFP) (lower panel). The panel on the left shows sections stained for EGFP (green) and cell nuclei (blue), while the panel on the right shows live
fluorescence images.
H Retinas from mice that were intravitreally injected were similarly analyzed.
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1182drives expression mostly in type 5, 6, and 7 bipolar cells and
showed a fourfold increase in the level of expression in the AAV2/
8BP2-4 × GRM6-CatCh-EGFP pool of cells; lhx4 drives expression in
a subset of bipolar cells terminating between chat strata and showed
a 13.6-fold increase in expression; the rod-bipolar-cell-specific prkc-
a showed a 10.4-fold increase, and the pan-ON-bipolar cell marker
Grm6 showed a 8.6-fold increase in expression. The high expression
of the rod-bipolar-cell-specific protein PKCa in the GFP-pool reflects
the high proportion of rod-bipolar cells in the ON-bipolar cell popu-
lation. Immunostaining for the PKCa protein is shown in retinas of
mice subretinally injected with the 4 × GRM6-CatCh-EGFP construct
in wild-type AAV2/8 compared to AAV2/8BP2 virus (Fig 3I).
It is also worth noting that no rhodopsin expression was detected
from rod photoreceptors, which comprise 70% of the retinal cells,
in the RNA from the AAV2/8BP2-4 × GRM6-transduced cell popula-
tion (Supplementary Fig S7). These results offer us a reasonable
estimate of the percentage of ON-bipolar cells we can transduce in
the mouse retina. The ON-bipolar cells comprise approximately 7%
of the total retinal cells in mice (Jeon et al, 1998), and from FACS
data, we find 5% transduction of retinal cells following subretinal
injection of the AAV2/8BP2-4 × GRM6-CatCh-EGFP virus. TrpM1L-
immunolabeling suggests that 83% of these cells are the target ON-
bipolar cells (Fig 3E). Therefore, this novel vector is transducing an
estimated 59% of ON-bipolar cells. This figure is supported by the
TrpM1L-colocalization counts (Fig 3D). However, it is arguably a
conservative estimate, and total cell counts on flat-mounted retinas
transduced with viruses carrying 4 × GRM6-EGFP suggest the upper
limit of transduction (Fig 3B).
Optogenetic stimulation of AAV2/8BP2-transduced ON-bipolar
cells in rd1 retina
In order to test the efficiency of the combined AAV2/8BP2 capsid
and 4 × GRM6 promoter in optogenetic stimulations, we injected
rd1 mice (which lack photoresponses after 1 month of age) sub-
retinally with AAV2/8BP2-4 × GRM6-CatCh-EGFP or AAV2/8-
4 × GRM6-CatCh-EGFP and recorded from ganglion cells of mice
between 12 and 14 weeks of age using multi-electrode arrays. We
were unable to detect any ganglion cell photoresponses in mice
injected with AAV2/8-4 × GRM6-CatCh-EGFP except in intrinsically
photosensitive retinal ganglion cells (results not shown). However,
in mice injected with AAV2/8BP2-4 × GRM6-CatCh-EGFP, ganglion
cells responded to light stimulation with short latency, high-
frequency spiking (Fig 4). Unlike in previous reports (Lagali et al,
2008; Doroudchi et al, 2011), we found responses from ON, OFF,
and ON-OFF cells (Fig 4A), suggesting that both rod-bipolar and
cone ON-bipolar cells were driving ganglion cells. Notably, the aver-
age peak firing rate of the recorded ganglion cells reached approxi-
mately 100 Hz (Fig 4B and D), and we found several ganglion cells
with peak firing in the range of 120–180 Hz (Fig 4B). This contrasts
with a previous report using AAV-delivered channelrhodopsin-2
stimulation of ON-bipolar cells where the firing frequency reached
20–25 Hz. As shown before (Lagali et al, 2008), we found that stim-
ulation with larger light spots evoked less efficient stimulation than
with smaller spots, suggesting the presence of lateral inhibition.
AAV2/8BP2-mediated transduction of ON-bipolar cells in
human retina
In order to determine whether AAV2/8BP2 is capable of transducing
human bipolar (and other) retinal cells, the AAV2/8BP2 capsid
carrying a cytomegalovirus (CMV) promoted EGFP cDNA was used
to infect human retinal explants. The CMV promoter was used as
the explant system shows downregulation of expression of mGluR6
(data not shown), and CMV has previously been shown to function
in this tissue system (Fradot et al, 2011). As shown in Supplemen-
tary Fig S8, human ON-bipolar cells were GFP-positive and also
labeled by immunofluorescence with an antibody against Goa.
Discussion
It is most likely that early human trials of optogenetics in the coming
years will focus on bipolar cells and persisting cones, which have
lost light sensitivity. While headway has been made in achieving
viral-mediated transduction and restoring function in the cones of
blind mouse retinas in vivo (Busskamp et al, 2010), efficient viral-
mediated transduction of optogenetic channels has not been possible
in bipolar cells. Nonetheless, Lagali et al (2008) demonstrated that
some functional properties of image processing could be restored in
rd1 retinas even where only 7% of the bipolar cells express ChR2
delivered by electroporation. Moreover, the ChR2-mediated signals
were relayed to the visual cortex and resulted in improvements in
visual behavioral tasks. These results hold significant promise for
therapeutic outcomes when both the number of bipolar cells express-
ing the channel and the level of channel expression are increased.
Achieving these enhanced levels of expression is the primary goal of
this paper. The library screen used to select a virus was designed to
Figure 3. Quantitative analysis of transduction properties of AAV8BP2 with a bipolar-cell-specific promoter construct.
A 10× images of sections from WT mice subretinally injected with AAV2/8(4 × GRM6-EGFP) and AAV2/8BP2(4 × GRM6-EGFP). The sections were stained for EGFP
protein expression (green) and for the cell nuclei (blue).
B Unfixed and unstained whole-mount images of the cell body, axonal and dendritic regions of the bipolar cells from the injected retinas taken at 40× magnification.
C The fluorescent spot counts on local z-stack projections spanning the cell body of these retinas (n = 6, P = 0.01).
D–F Cell counts of colocalization of the red (TrpM1L) and green (EGFP) channels (n = 4), with the counts normalized to total red cells (D, P = 0.04) or to total green
cells (E). A representative image of the labeled retinal sections used for cell counting is shown (F).
G FACS analysis of subretinally and intravitreally injected retinas carried out at 3 weeks post-injection. Representative dot-plot of the fluorescence intensity range for
the subretinally injected retinas with GFP versus APC-a (n = 6). AAV2/8 injected retina is shown in the top panel while AAV2/8BP2-injected retina is shown in the
bottom panel.
H The FACS intensity range divided across seven regions, Fr8 to Fr14, with the percentage of fluorescent cells shown on the y-axis.
I A representative 40× image of a section from subretinally injected retinas stained for EGFP (green), cell nuclei (blue), and the rod-bipolar cell marker PKCa (red).
J Expression of kcng4, lhx4, prkca, and grm6 in cells of sorted fractions Fr12 to Fr14 (highlighted by a red box in the upper panel of Fig 3H) relative to expression in
unsorted cells from total retina.
◂
ª 2014 The Authors EMBO Molecular Medicine Vol 6 |N o9 | 2014
Therese Cronin et al Bipolar cell transduction to restore vision EMBO Molecular Medicine
1183encompass as much diversity as possible taking into consideration
the loss of degeneracy that occurs during library transformation,
expansion, and packaging. Many variations on AAV libraries have
been done to date, and the success of these libraries relies heavily on
the screening process used. We consider the in vivo screen using the
mglur6-gfp mouse key to the isolation of this virus. Furthermore, the
preferential uptake of WT AAV2/8 by non-bipolar cells validated a
selection strategy whereby we could isolate variants against a satu-
rating background of WT virus.
The synthetic AAV and promoter combination described here
will allow us to further probe the molecular basis of bipolar cell
function. However, its immediate promise is a strong candidate for
the delivery of light-sensing molecules to the bipolar cell. Bipolar
cell-based strategies, which use inner retinal processing, might be
used after the loss of cone vision, but before the massive reorganiza-
tion of the inner retina that probably occurs at later stages of retinal
degeneration (Jones et al, 2003). Preliminary data from experiments
in human retinal explants show GFP-positive ON-bipolar cells
after infection with AAV2/8BP2 (Supplementary Fig S8), thereby
providing evidence that the viral tropism and transgene expression
characteristics in mice and humans are similar. Such transduction
of human explants could not be achieved using the unmodified
AAV2/8 (Busskamp et al, 2010). This argues that the strategy devel-
oped in mice can ultimately be extrapolated to humans. Further
studies, in progress, aim to evaluate variables that may affect the
translational potential. In summary, the work described here is an
essential first step in the development of optogenetic agents for the
reversal of advanced forms of blindness.
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1184Materials and Methods
Terminology
Expression construct for capsid genes isolated from the AAV
genome is referred to as pAAV. The plasmid expressing the unmu-
tated AAV8 capsid gene is referred to as pAAV8, and the plasmid
expressing the mutated AAV8 capsid gene is referred to as
pAAV8BP. The virus carrying the AAV2 Inverted Terminal Repeats
(ITRs) and with the unmutated AAV8 capsid is referred to as
AAV2/8, while the virus carrying the AAV2 ITRs and with the
mutated AAV8 capsid is referred to as AAV2/8BP. For simplicity,
the recombinant AAV2/8 virus with unmutated capsid is referred to
as the “wild-type” virus.
AAV library production
The plasmid pRed-Caps-Lib was created incorporating the AAV8
rep/cap gene expressed from a PGK promoter in reverse orientation
to the dsRed gene expressed from a CMV promoter. This double
cassette was cloned between the AAV2 ITRs. A fragment of the
AAV8 rep/cap gene between the sbf1 and mlu1 sites was synthe-
sized by the company DNA2.0 (https://www.dna20.com/). This
region includes the amino acids 587–595 (counting from the first
amino acid of AAV8 vp1), and mutations were incorporated at each
of these nine positions. The plasmid pRed-Caps-Lib was linearized
with sbf1 and mlu1. A second sbf1 site further upstream was initi-
ally mutated using a site-directed mutagenesis kit (Agilent Technol-
ogies, Wilmington, DE), prior to cloning. It was crucial that no
single-cut, partially digested backbone from the wild-type plasmid
escaped during the cloning as it would contaminate and saturate the
library. Initially therefore a stuffer element was cloned into the
region of the wild-type capsid between the sbf1 and mlu1 sites to
ensure adequate separation of double-cut and partially digested
single-cut fragments on a gel. This 3.2-kb stuffer element also
carried a kanamycin resistance containing region. Upon restriction
enzyme digest of this “pre-library” plasmid (Supplementary Fig
S1A) with sbf1 and mlu1, the larger 3.2-kb kanamycin-containing
element was excised and replaced with the 370-bp library fragment
carrying the 9 NNK residues. As further control, the transformation
was screened for no-growth on agar-kanamycin plates. Hence, the
final library plasmid contains 4.27 kb between the ITRs as shown in
Supplementary Fig S1B. The synthesized mutated region was ligated
with the sbf1/mlu1 digested backbone using T4 DNA ligase (New
England Biolabs). Three ligation reactions were pooled, ethanol
precipitated, and electroporated into DH10b electrocompetent
bacteria (Invitrogen).
To titrate the plasmid library, a series of tenfold dilutions from
100 ll of the 1-ml starter culture of transformation broth were
plated on agar-ampicillin plates. This sample was taken from the
starter culture after 30 min of incubation of the newly transformed
bacteria. We make the assumption that each colony is derived
from a single random member of the library and that minimal
divisions have taken place prior to plating. Therefore, colony-
counting can give an estimate of library diversity and a plasmid
library diversity of 2.6 × 10
5 cfu/ml was counted. The remainder
of the starter culture was used to inoculate 2 l of broth to prepare
rep/cap plasmid library DNA for AAV production. (Note: To
maximize diversity of the plasmid library, the NNK mutagenesis
saturation strategy was applied which theoretically covers all 20
amino acids at each of the 9 sites yielding a potential degeneracy
at the amino acid level of 5.12E9. It is clear that only a fraction of
the combinations theoretically generated was represented in the
recovered library and the efficiency could be improved with
further optimization of the cloning process). The AAV library was
prepared by cotransfection using the plasmid library DNA and a
helper plasmid. This was carried out according to standard proce-
dure with some alterations: To minimize the transfection of
multiple different rep/cap genes into each cell (which would lead
to encapsidation of a non-“self-coding” genome), a low plasmid
concentration was used for the triple transfection (Maheshri et al,
2006)—150 ng of rep/cap library plasmid was used per 150-mm
confluent HEK293 cell culture plate. Ultimately, the transfected
cell lysates, and broths from 70 confluent 150-mm transfected
plates were used to prepare the library. The broth and benzonase-
treated lysates were concentrated 20-fold using a tangential flow
filtration system before virus purification using a discontinuous
iodixanol gradient (Sigma, Optiprep). To estimate the infectious
titer of the AAV library, HEK293 cells were seeded at 50% conflu-
ency on poly-L-lysine-coated glass coverslips across 10 wells of a
24-well plate. Serial dilutions of the AAV library were added
directly onto each well. After 72 h, the cells were fixed with 4%
paraformaldehyde (PFA) and washed with PBS and dH2O. The
number of fluorescent cells from the well with highest dilution
factor that still showed infection was recorded and multiplied by
the dilution factor to give the number of infectious units per
microliter (IU/ll).
AAV preparation
Standard AAV production of individual viruses was performed as
previously described (Grieger et al, 2006) by triple transfection of
HEK293 cells with branched polyethylenimine (PEI) (Polysciences,
no. 23966) with a plasmid containing the transgene between the
ITRs of AAV2, the AAV-helper plasmid encoding Rep2 and Cap for
serotype variants, and the pHGTI-Adeno1 plasmid harboring helper
adenoviral genes (both kindly provided by C. Cepko, Harvard Medi-
cal School, Boston, MA, USA). The HEK293 cells express the helper
E1A/E1b gene (American Type Culture Collection, catalogue
number CRL-157). Vectors were purified using a discontinuous
iodixanol gradient (Sigma, Optiprep). Encapsidated DNA was
quantified by TaqMan RT–PCR (using primers “AAV titer”, Supple-
mentary Table S1), following denaturation of the AAV particles
by proteinase-K, and titers were calculated as genome copies (gc)
per ml.
In vitro titer assay for individual AAV capsid variants
Capsid genes were cloned in an AAV packaging plasmid for vector
production, and used for small-scale vector preparations encoding
firefly luciferase to obtain the titer shown (Fig 1E). Physical particle
titers were established by TaqMan qPCR (Supplementary Fig S3).
Subsequently, AAV2/8BP variants were assayed for transduction at
equal multiplicity of infection onto HEK293 cells. For large-scale
viral titer, the encapsidated DNA was quantified by TaqMan
RT–PCR (using primers “AAV titer”, Supplementary Table S1),
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1185following denaturation of the AAV particles by proteinase-K, and
titers were calculated as genome copies (gc) per ml (Fig 1F).
Mice
The GRM6-EGFP mice were kindly provided by Dr. Noga Vardi
(University of Pennsylvania). C57Bl/6J were obtained from breeding
stock at the Jackson Laboratory (Bar Harbor, ME), and C57Bl/6NCrl
and C3HeN mice from breeding stock at the Charles River Laborato-
ries (L’Arbresle Cedex, France). All animal experiments and proce-
dures performed in the US were reviewed and approved according
to the guidelines set out in the National Institutes of Health’s Guide
for Care and Use of Laboratory Animals with approval by the
University of Pennsylvania Institute for Animal Care and Use
Committee (IACUC), protocols 804546,804543. All animal experi-
ments and procedures performed in Switzerland were approved by
the Swiss Veterinary Office. For these experiments, both eyes of the
mice were injected using a stereotactic setup. The same researcher
(JJ) carried out all the injections to compare AAV2/8BP2 with the
normal recombinant virus. Up to 2 ll of virus, at titers ranging from
1 × 10
10 gc/ml to 1 × 10
13 gc/ml were injected into both eyes. The
numbers of mice used are outlined in Table 2.
Construction of the 4 × Grm6 promoter
The 4 × Grm6 promoter construct was created by iterative cloning
of the single Grm6 enhancer element contained within the pGrm6-
CY expression plasmid (Lagali et al, 2008). First, the Grm6 enhancer
element was amplified by PCR using the primers “Grm6 enhancer”
(Supplementary Table S1) to generate XbaI and SspI restriction sites
upstream of the Grm6 sequence, and a SalI site at the 30 terminus of
the enhancer element. The PCR product was blunt-ended with the
Klenow fragment of DNA polymerase I and then digested with SalI.
This DNA fragment was subsequently inserted into the SspI/SalI
double-digested pGrm6-CY plasmid to create two copies of the Grm6
enhancer element in tandem. The resulting plasmid was digested
with XbaI and SspI, and the PCR product generated above was
inserted via the XbaI-cut 50 end and Klenow-blunted 30 end. The
previous subcloning step was repeated to insert an additional copy
of the enhancer element to yield the 4 × Grm6 promoter construct.
Immunohistochemistry and imaging
Retinas were dissected from the eyecup, fixed in 4% (wt/vol) para-
formaldehyde in PBS for 20–30 min, and washed overnight in PBS.
They were incubated in 30% sucrose for 30 min at 22–23°C before
being submitted to three freeze–thaw cycles. Wholemounts or 150-
lm vertical sections cut with a Leica VT1000S vibratome were used.
The retinas were then incubated in blocking solution (10% normal
donkey serum (vol/vol, Chemicon), 1% bovine serum albumin (wt/
vol), and 0.5% Triton X-100 (vol/vol) in PBS, pH 7.4) for 1 h.
Primary and secondary antibody applications were done in 3%
normal donkey serum, 1% bovine serum albumin, 0.02% sodium
acid (wt/vol), and 0.5% Triton X-100 in PBS. Primary antibodies
[rabbit antibody to GFP (1:200; Molecular Probes) and goat anti-
body to ChAT (1:300; Chemicon)] were applied for 3–7 days. In
addition, an antibody against the long isoform of TrpM1
(NP_001034193.2) was raised and purified by Eurogentec. We
designed this antibody to target a TrpM1L-isoform-specific epitope
(C+PQISRSALTVSDRPE) and used it for ON-bipolar cell labeling.
Secondary antibodies were purchased from Invitrogen (Alexa Fluor
488, Alexa Fluor 555, Alexa Fluor 633) or from Jackson Laboratory
(Cy3, Cy5) and used at a concentration of 1:200. The wholemounts
and retinal sections were mounted on slides with ProLong Gold
antifade reagent (Molecular Probes). Confocal three-dimensional
scans of 1024 × 1024 pixel images in a z-stack were taken with a
Zeiss LSM 700 confocal microscope using three excitation laser lines
(405 nm for DAPI, 488 nm for GFP, and 633 nm for ChAT) and
imaged using Zen imaging software (Carl Zeiss MicroImaging
GmbH). Images were processed using Fiji (http://fiji.sc/wiki/
index.php/ImageJA). Equivalent processing was carried out for both
test and control 32-bit images. A z-projection was made on fixed
stack size, and the gamma changed to visualize low-value pixels.
The images were saved as RGB color and imported into Adobe Illus-
trator. For wholemount retinas, a local stack was made spanning
the bipolar cell body in 40× images of the retinas, and the spot
detection performed using fixed threshold in Fiji. For the colocaliza-
tion study, slices from a stack of 40× images acquired for the red
and green color channels were processed as composite in Fiji. The
“cell counter” plug-in was used to record cells in different color
channels using fixed brightness and contrast settings.
Table 2. The numbers of mice used in these experiments.
Number
of mice Strain Age Procedure Relevant figure
10 Grm6-EGFP Injected at 10 weeks, tested at 13 weeks Subretinal injection of AAVlib 1A, B, C, D
8 C57Bl6 Injected at 5 weeks, tested at 10 weeks Subretinal injection of AAV variants 2A, S4
6 C57Bl6 Injected at 6 weeks, tested at 10 weeks Intravitreal injection of AAV variants 2B, S4
8 C57Bl6 Injected at 8 weeks, tested at 12 weeks Subretinal injection to quantitatively
test AAV2/8BP2(EF1a-EGFP).
2D, E, F
15 C57Bl6 Injected at 8 weeks, tested at 12 weeks Subretinal injection to test
AAV2/8BP2(4 × Grm6-EGFP)
2G, 3A, D, E, F, G, H, I, J
6 C57Bl6 Injected at 8 weeks, tested at 12 weeks Intravitreal injection to test
AAV2/8BP2(4 × Grm6-EGFP)
2H, 3B, C, H
5 C3Hen Injected at 10 weeks, tested at 14 weeks. Subretinal injection to test
AAV2/8BP2(4 × Grm6-CHr2d-EGFP) responses
4A, B, C, D
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Retinas were dissociated as previously described (Siegert et al,
2012). The retinas from left and right eyes were processed sepa-
rately and counted as separate experiments. Cells were sorted
immediately following dissociation on a BD FACSAria cell sorter
(Becton Dickinson), and 80,000 cells were collected directly in
600 ll of Trizol LS (Life Technologies) for RNA purification
according to the manufacturer’s protocol. The RNA was quanti-
fied using a NanoDrop, and all samples normalized to 35 ng/ll
concentration before reverse transcription using random hexamer
primers (Roche) and transcriptor reverse transcriptase (Roche).
The cDNA was diluted 1/5 and a 3 ll volume used in the qPCR.
For the TaqMan assay, the probes outlined in Supplementary
Table S2 were used (Actb, Rho, Grm6, TrpM1L, Opn swl, and
Opn mwl) with universal master mix (Applied Biosystems). For
SYBR Green assays, the desalted primers outlined in Supplemen-
tary Table S1 were used (Prkca, Kcng4, Lhx4, Actb) with SYBR
Green reagent (Invitrogen). The mouse b-actin gene was used to
normalize the expression levels in the TaqMan reaction, and
18srRNA used in the SYBR Green reaction. Samples were loaded
in triplicate where possible. Relative quantification was performed
as previously described (Pfaffl, 2001).
Human retinal explants
Use of human tissue was in compliance with local and federal regu-
lations. De-identified tissue was provided by Miracles in Sight,
North Caroline Eye Bank, Winston-Salem, NC, USA, an organization
which provides ocular tissue to assist researchers to ultimately find
cures for eye conditions/diseases. Experiments conformed to the
principles set out in the WMA Declaration of Helsinki and the NIH
Belmont Report. A postmortem human retina was obtained and
treated with AAV2/8BP2-CMV-GFP at a titer of 4.38 × 10
12 gc/ml
(and delivering 5.5E10 gc) using methods described (Fradot et al,
2011). Immunofluorescence was carried out 12 days after infection
using a mouse primary antibody against Goa to label ON-bipolar
cells (Chemicon; mAB3073; 1:500), an Alexa fluorophore-
conjugated secondary antibody (Invitrogen, Grand Island, NY,
USA), DAPI, and a FV1000 confocal microscope (Olympus, Center
Valley, PA, USA).
Electrophysiology
The retina was isolated under dim red light in Ringer’s medium (in
mM: 110 NaCl, 2.5 KCl, 1 CaCl2, 1.6 MgCl2, 10 D-glucose, 22
NaHCO3) bubbled with 5% CO2/95% O2. The retina, ganglion side
down, was then immobilized on the multi-electrode array by gentle
pressing with a cell culture membrane (Transwell 3450-Clear)
having hexagonally arranged holes with 200 lm diameter and a
center-to-center distance of 400 lm. For the duration of the experi-
ment, the retina was perfused with Ringer’s medium bubbled with
5% CO2/95% O2, at a flow rate of 1.5 ml/min at 35°C. Extracellular
voltage was measured with a multi-electrode array (MEA1060 Up-
BC amplifier, Multichannel Systems) at 20 kHz. The array was fixed
on a motorized table (Scientifica). Light stimulus was generated
using a DLP projector (PLUS U137SF) and projected onto the retina
by the condenser lens of an inverted microscope (Nikon TE300).
The spectrum of the stimulus light was determined using a
spectrophotometer (Ocean Optics USB2000), and the light intensity
was measured using a power meter (Thorlabs S130VC). The stimu-
lation intensity was calculated by integrating the product of the
projector spectrum and the normalized absorption spectrum of
CatCh. The recorded voltage was bandpass-filtered (400–4,000 Hz),
and spikes were sorted using the UltraMegaSort software (Kleinfeld
Lab, University of California, San Diego). Spike frequency was
calculated using 50 ms moving bins. Intrinsically photosensitive
retinal ganglion cells were discriminated by their delayed spiking.
For quantification, we only used spike frequency values in the first
200 ms after light onset or offset.
Statistics and software
CLC Main Workbench was used for sequence annotation and in
silico cloning (CLC-bi, Denmark). PyMOL was used for 3-D visuali-
zation of the mutated capsid structures (The PyMOL Molecular
Graphics System, Version 1.5.0.4, Schro ¨dinger, LLC.). Zen imaging
software (Carl Zeiss MicroImaging GmbH) was used to load images
taken by confocal microscopy, and these images were processed
using Fiji (http://fiji.sc/wiki/index.php/ImageJA). StepOne soft-
ware v2 (Applied Biosystems, Life Technologies, Switzerland) was
The paper explained
Problem
Excellent safety and efficacy data relating to AAV-mediated retinal
gene augmentation therapy have been collected in early- and late-
phase clinical trials in children and adults with a rare, early onset
blindness called Leber’s Congenital Amaurosis. While this approach
could theoretically be used to reverse blindness in other inherited
diseases, there are practical limits to its utility, including requirements
for intervention before the target cells (photoreceptors/retinal pigment
epithelium) have died and identity of the disease-causing gene. There
is a large unmet need for a therapy that could be used in any inher-
ited or acquired form of blindness. One possibility for such a broad-
based therapy lies in the burgeoning field of optogenetics. In
advanced stages of disease where photoreceptors are no longer viable,
the inner retinal and CNS visual pathway circuitry can be harnessed
by rendering the second-order retinal neurons light-sensitive through
delivery of an appropriate optogenetic channel. Until now, this was
not possible due to a lack of vectors, which can efficiently and stably
transduce such neurons, bipolar cells.
Results
The AAV2/8 recombinant virus was used as a template for library
screening of viral capsid mutants that would efficiently transduce
bipolar cells. In parallel, a bipolar-cell-specific promoter was opti-
mized for strong, cell-specific expression. One capsid variant, together
with a transgene cassette carrying the enhanced promoter, showed
high and stable levels of transduction of bipolar cells. This vehicle was
used to deliver a channelrhodopsin optogenetic molecule to the reti-
nas of the rd1 mouse. The retina of this mouse typically shows no
response to visual stimuli; however, when transduced with the novel
channelrhodopsin-expressing virus, robust spiking responses were
recorded.
Impact
The engineering of this vector represents an essential step in the
development of optogenetic agents for the reversal of advanced forms
of blindness.
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1187used to process qPCR data. Excel (Microsoft Office) and GraphPad
Prism 6 (GraphPad Software, Inc., CA, USA) were used for all other
statistical calculations. The Mann–Whitney U-test was used to deter-
mine significance in differences between pairs. Data were expressed
as the mean   standard error of mean (SEM) where n ≥ 7, and
mean   standard deviation (SD) where n < 7. In the figures,
different levels of significance are indicated by * for P ≤ 0.05,
**P < 0.01.
Supplementary information for this article is available online:
http://embomolmed.embopress.org
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